

Event Calendar

View recent presentations and learn more about upcoming events.

Disclaimer:

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Tab:

Upcoming Events

Iptacopan (LNP023) update

Jun 22, 2021

[Watch the webcast](#) ^[1]

14:30 CEST - 13:30 BST - 08:30 EDT

Guggenheim Biopharma's Next Decade

Jun 23, 2021

Second quarter results 2021

Jul 21, 2021

Basel, Switzerland

Third quarter results 2021

Oct 26, 2021

Basel, Switzerland

Recent Events ^[2]

dbAccess Conference

Jun 16-17, 2021

Berlin, Germany

Citi European Healthcare Conference

Jun 15, 2021

Goldman Sachs Conference

Jun 09-10, 2021

Oncology update

Jun 08, 2021

Watch the webcast ^[3]

Download the presentation (PDF 2.5 MB) ^[4]

Bernstein Annual Strategic Decisions

Jun 04, 2021

Jefferies Healthcare Conference

Jun 03, 2021

Webinar: Materiality and impact valuation as key enablers of corporate purpose

Jun 01, 2021

Register for the event ^[5]

UBS Global Healthcare Conference

May 24, 2021

Berenberg Conference

May 18, 2021

Cardiovascular update

May 18, 2021

[Watch the webcast](#) [6]

[Download the presentation \(PDF 3.6 MB\)](#) [7]

[Download the podcast \(MP3 43 MB\)](#) [8]

Bank of America ML Healthcare Conference

May 11, 2021

First quarter results 2021

Apr 27, 2021

Basel, Switzerland

Media release

[English \(PDF 0.2 MB\)](#) [9]

[Deutsch \(PDF 0.2 MB\)](#) [10]

[Français \(PDF 0.2 MB\)](#) [11]

[Interim financial report \(PDF 0.4 MB\)](#) [12]

[Watch the webcast](#) [13]

[Read the presentation transcript](#) [14]

[Download the podcast \(MP3 40 MB\)](#) [15]

[Download the interactive presentation \(PDF 7.2 MB\)](#) [16]

[Novartis ESG Update - April 28, 2021 \(PDF 0.3 MB\)](#) [17]

Guggenheim Protein Degradation Day

Mar 16, 2021

Barclays Healthcare Conference

Mar 09, 2021

Annual General Meeting

Mar 02, 2021
Basel, Switzerland

[Visit the Annual General Meeting section](#) ^[18]

Cowen Healthcare Conference

Mar 01, 2021

Leerink Global Healthcare Conference

Feb 25, 2021

[Watch the webcast](#) ^[19]

Entresto® FDA Label Expansion Investor Q&A Call

Feb 17, 2021
Basel, Switzerland

[Watch the webcast](#) ^[20]

[Download the podcast \(MP3 22 MB\)](#) ^[21]

[Download the presentation \(PDF 0.6 MB\)](#) ^[22]

Citi Immuno-Oncology Conference

Feb 17, 2021

Guggenheim Healthcare Talks | Oncology Day

Feb 11, 2021

Materiality Assessment Webinar: Dialogue matters – support us to spur positive impact

Feb 08, 2021

[Watch the webcast](#) ^[23]

[Download the presentation \(PDF 3.3 MB\)](#) ^[24]

Fourth Quarter and Full Year Results 2020 and Annual Report 2020 publication

Jan 26, 2021
Basel, Switzerland

Media release:

[English \(PDF 0.2 MB\)](#) ^[25]

[Deutsch \(PDF 0.2 MB\)](#) ^[26]

[Français \(PDF 0.2 MB\)](#) ^[27]

[Condensed financial report \(PDF 0.9 MB\)](#) ^[28]

[Watch the webcast](#) ^[29]

[Read the presentation transcript](#) ^[30]

[Download the podcast \(MP3 45 MB\)](#) ^[31]

[Download the presentation \(PDF 5.6 MB\)](#) ^[32]

[Access our interactive slide deck \(PDF 12 MB\)](#) ^[33]

[Novartis ESG Update - January 27, 2021 \(PDF 0.5 MB\)](#) ^[34]

[Download the Annual Report 2020 \(PDF 3.5 MB\)](#) ^[35]

[Visit the Novartis Annual Reporting Suite section](#) ^[36]

J.P. Morgan Healthcare Conference

Jan 11, 2021
Virtual / San Francisco, USA

[Listen to the webcast](#) ^[37]

[Download the presentation \(PDF 1.0 MB\)](#) ^[38]

[2020 Archive](#) ^[39]

Co-Creating Impact Summit

Dec 09, 2020

[Register for the event](#) ^[40]

[Download the agenda \(PDF 0.1 MB\)](#) ^[41]

Société Générale Premium Review Conference

Dec 02, 2020
Virtual / Paris, France

Berenberg European Conference

Dec 02, 2020
Virtual / London, UK

Redburn CEO Conference

Dec 01, 2020
Virtual / London, UK

Meet Novartis Management

Nov 24, 2020

[Download the agenda \(PDF 0.1 MB\)](#) ^[42]

[Visit the Event Center](#) ^[43]

UBS European Conference

Nov 11, 2020
London, UK

Inaugural Healthcare CEO Summit

Nov 05, 2020
Baltimore, USA

Webinar: Measuring and evaluating social outcomes of access initiatives

Oct 28, 2020

[Register for the event](#) ^[44]

Third quarter results 2020

Oct 27, 2020
Basel, Switzerland

Media release

[English \(PDF 0.2 MB\)](#) ^[45]

[Deutsch \(PDF 0.2 MB\)](#) ^[46]

[Français \(PDF 0.3 MB\)](#) ^[47]

[Interim financial report \(PDF 0.8 MB\)](#) ^[48]

[Watch the webcast](#) ^[49]

[Read the presentation transcript](#) ^[50]

[Download the podcast \(MP3 41 MB\)](#) ^[51]

[Download the presentation \(PDF 2.7 MB\)](#) ^[52]

[Novartis ESG Update - October 28, 2020 \(PDF 0.5 MB\)](#) ^[53]

Bank of America Merrill Lynch Global Healthcare Conference

Sep 18, 2020

London, UK

Novartis ESG Investor Event

Sep 01, 2020

[Watch the webcast](#) ^[54]

[Download the presentation \(PDF 3.2 MB\)](#) ^[55]

[Read the media release](#) ^[56]

Kesimpta® FDA Approval Investor Call

Aug 21, 2020

Basel, Switzerland

[Watch the webcast](#) ^[57]

[Download the podcast \(MP3 28 MB\)](#) ^[58]

[Download the presentation \(PDF 1.0 MB\)](#) ^[59]

ESG materiality assessment webinar: Wealth and Health - Reframing healthcare costs as economic investments

Jul 30, 2020

[Register for the event](#) ^[60]

Second quarter results 2020

Jul 21, 2020

Basel, Switzerland

Media release

[English \(PDF 0.2 MB\)](#) ^[61]

[Deutsch \(PDF 0.2 MB\)](#) ^[62]

[Français \(PDF 0.3 MB\)](#) ^[63]

[Interim financial report \(PDF 0.8 MB\)](#) ^[64]

[Watch the webcast](#) ^[65]

[Read the presentation transcript](#) ^[66]

[Download the podcast \(MP3 44 MB\)](#) ^[67]

[Download the presentation \(PDF 2.6 MB\)](#) ^[68]

[Novartis ESG Update - July 24, 2020 \(PDF 0.6 MB\)](#) ^[69]

ESG materiality assessment webinar: Embracing double materiality in responding to the COVID-19 pandemic

Jun 25, 2020

[Register for the event](#) ^[70]

JP Morgan European Healthcare Conference

Jun 18, 2020

London, UK

Citi European Healthcare Conference

Jun 17, 2020

London, UK

Oncology Pipeline Update

Jun 15, 2020

Basel, Switzerland

[Watch the webcast](#) ^[71]

[Download the podcast \(MP3 44 MB\)](#) [72]

[Download the presentation \(PDF 3.3 MB\)](#) [73]

ESG materiality assessment webinar: sickle cell disease

May 28, 2020

[Register for the event](#) [74]

UBS Virtual Global Healthcare Conference

May 19-20, 2020

First quarter results 2020

Apr 28, 2020

Basel, Switzerland

Media release

[English \(PDF 0.2 MB\)](#) [75]

[Deutsch \(PDF 0.2 MB\)](#) [76]

[Français \(PDF 0.2 MB\)](#) [77]

[Interim financial report \(PDF 0.6 MB\)](#) [78]

[Read the presentation transcript](#) [79]

[Download the podcast \(MP3 45 MB\)](#) [80]

[Download the presentation \(PDF 3.0 MB\)](#) [81]

[Novartis ESG Update – April 29, 2020](#) [82]

Zolgensma® MDA Data Investor Call

Mar 30, 2020

Basel, Switzerland

[Download the podcast \(MP3 30 MB\)](#) [83]

[Download the presentation \(PDF 1.1 MB\)](#) [84]

Bernstein DCAT

Mar 25, 2020
New York, USA

Cowen Healthcare Conference

Mar 04, 2019
Boston, USA

Annual General Meeting

Feb 28, 2020
Basel, Switzerland

[Visit the Annual General Meeting section](#) ^[18]

Leerink Global Healthcare Conference

Feb 27, 2020
New York, USA

Guggenheim Healthcare Talks

Feb 13, 2020
New York, USA

Fourth Quarter and Full Year Results 2019 and Annual Report 2019 publication

Jan 29, 2020
Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) ^[85]

[Deutsch \(PDF 0.1 MB\)](#) ^[86] [Français \(PDF 0.2 MB\)](#) ^[87]

[Condensed financial report \(PDF 0.6 MB\)](#) ^[88]

[Read the presentation transcript](#) ^[89]

[Download the podcast \(MP3 43 MB\)](#) ^[90]

[Download the presentation \(PDF 3.6 MB\)](#) ^[91]

[Download the Annual Report 2019 \(PDF 4 MB\)](#) ^[92]

[Visit the Novartis Annual Reporting Suite section](#) ^[36]

J.P. Morgan Healthcare Conference

Jan 13, 2020
San Francisco, USA

[Read the transcript](#) ^[93]

[Download the presentation podcast \(MP3 10 MB\)](#) ^[94]

[Download the Q&A podcast \(MP3 12 MB\)](#) ^[95]

[Download the presentation \(PDF 1.4 MB\)](#) ^[96]

2019 Archive ^[97]

Citi Healthcare Conference

Dec 11, 2019
New York, USA

R&D Day

Dec 05, 2019
London, UK

[Read the media release](#) ^[98]

[Download the agenda \(PDF 0.1 MB\)](#) ^[99]

[Download the presentation \(PDF 8.1 MB\)](#) ^[100]

Berenberg European Corporate Conference

Dec 04, 2019
London, UK

Novartis enters into agreement to acquire The Medicines Company

Nov 25, 2019
Basel, Switzerland

[Read the media release](#) ^[101]

[Read the presentation transcript](#) ^[102]

[Download the podcast \(MP3 26 MB\)](#) [103]

[Download the presentation \(PDF 0.6 MB\)](#) [104]

Jefferies London Healthcare Conference

Nov 20, 2019

London, UK

UBS European Conference

Nov 12, 2019

London, UK

Wolfe Healthcare Conference

Nov 06, 2019

New York, USA

ZKB Swiss Conference

Nov 06, 2019

Zurich, Switzerland

Third quarter results 2019

Oct 22, 2019

Basel, Switzerland

Media release

[English \(PDF 0.1 MB\)](#) [105]

[Deutsch \(PDF 0.2 MB\)](#) [106]

[Français \(PDF 0.3 MB\)](#) [107]

[Interim financial report \(PDF 0.8 MB\)](#) [108]

[Read the presentation transcript](#) [109]

[Download the presentation \(PDF 2.3 MB\)](#) [110]

Beovu® FDA Approval

Oct 08, 2019
Basel, Switzerland

[Read the media release](#) [111]

[Download the presentation \(PDF 1.4 MB\)](#) [112]

[Download the podcast \(MP3 22 MB\)](#) [113]

Kisqali® MONALEESA-3 ESMO Data Investor Call

Oct 01, 2019
Basel, Switzerland

[Download the podcast \(MP3 14 MB\)](#) [114]

[Download the presentation \(PDF 1.8 MB\)](#) [115]

Bernstein's Strategic Decisions Conference

Sep 26, 2019
London, UK

Baader Investment Conference

Sep 24, 2019
Munich, Germany

Bank of America Merrill Lynch Global Healthcare Conference

Sep 18, 2019
London, UK

Ofatumumab (OMB157) ECTRIMS Data Investor Call

Sep 16, 2019
Basel, Switzerland

[Download the podcast \(MP3 26 MB\)](#) [116]

[Download the presentation \(PDF 1.1 MB\)](#) [117]

ESG Investor Event

Sep 09, 2019
London, UK

[Download the podcast \(MP3 40 MB\)](#) [118]

[Download the presentation \(PDF 4.8 MB\)](#) [119]

UBS Best of Switzerland Conference 2019

Sep 05-06, 2019
Zurich, Switzerland

Zolgensma® Update

Aug 07, 2019

[Read the media release \(PDF 0.4 MB\)](#) [120]

[Download the podcast \(MP3 16 MB\)](#) [121]

Second quarter results 2019

July 18, 2019
Basel, Switzerland

Media release

[English \(PDF 0.1 MB\)](#) [122]

[Deutsch \(PDF 0.1 MB\)](#) [123]

[Français \(PDF 0.2 MB\)](#) [124]

[Interim financial report \(PDF 0.6 MB\)](#) [125]

[Read the presentation transcript](#) [126]

[Download the podcast \(MP3 41 MB\)](#) [127]

[Download the presentation \(PDF 2.2 MB\)](#) [128]

JP Morgan European Healthcare Conference

Jun 20, 2019
London, UK

Citi European Healthcare Conference

Jun 19, 2019
London, UK

Wolfe Research Pipelines Unplugged

Jun 05, 2019
New York, USA

Vontobel Summer Conference

Jun 05, 2019
Interlaken, Switzerland

Jefferies Global Healthcare Conference

Jun 04, 2019
New York, USA

ASCO Investor Event

Jun 02, 2019
Chicago, USA

[Download the presentation \(PDF 0.8 MB\)](#) ^[129]

UBS Best of Europe Conference

May 29, 2019
New York, USA

Zolgensma® and Piqray® US FDA Approvals

May 27, 2019

Read the media releases:

[AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy \(SMA\)](#) ^[130]

[AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families](#) ^[131]

[Zolgensma US Prescribing Information \(PDF 0.3 MB\)](#) ^[132]

[FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer](#) ^[133]

[Download the presentation \(PDF 0.8 MB\)](#) ^[134]

[Download the podcast \(MP3 22 MB\)](#) [135]

Meet Novartis Management investor event in Boston

May 23, 2019
Boston, USA

[Read the media release](#) [136]

[Download the presentation \(PDF 7.8 MB\)](#) [137]

[Download the agenda \(PDF 0.1 MB\)](#) [138]

Novartis enters into agreement to acquire Xiidra®

May 09, 2019

[Read the media release](#) [139]

[Download the podcast \(MP3 18 MB\)](#) [140]

[Download the presentation \(PDF 0.8 MB\)](#) [141]

Zolgensma AAN Data Investor Call

May 08, 2019
Philadelphia, USA

[Download the podcast \(MP3 25 MB\)](#) [142]

[Download the presentation \(PDF 1.0 MB\)](#) [143]

First quarter results 2019

Apr 24, 2019
Basel, Switzerland

Media release

[English \(PDF 0.5 MB\)](#) [144]

[Deutsch \(PDF 0.4 MB\)](#) [145] [Français \(PDF 0.8 MB\)](#) [146]

[Interim financial report \(PDF 0.5 MB\)](#) [147]

[Read the presentation transcript](#) [148]

[Download the podcast \(MP3 41 MB\)](#) [149]

[Download the presentation \(PDF 1.4 MB\)](#) [150]

2017/2018 Results for Continuing Operations

Apr 24, 2019

[Download the presentation \(PDF 0.4 MB\)](#) [151]

Mayzent FDA Approval Investor Call

Mar 27, 2019

Basel, Switzerland

[Read the media release](#) [152]

[Download the presentation \(PDF 0.9 MB\)](#) [153]

[Download the podcast \(MP3 23 MB\)](#) [154]

Updated Alcon 20-F filed with the SEC

Mar 22, 2019

[Download the updated Alcon 20-F \(PDF 2.0 MB\)](#) [155]

[SEC filing](#) [156]

Kepler Cheuvreux Swiss Seminar

Mar 21, 2019

Zurich, Switzerland

Bernstein DCAT Day

Mar 18, 2019

New York, USA

Barclays Global Healthcare Conference

Mar 12, 2019

Miami, USA

Cowen Healthcare Conference

Mar 11, 2019
Boston, USA

Credit Suisse Global Healthcare Conference

Mar 06, 2019
London, UK

Leerink Global Healthcare Conference

Mar 01, 2019
New York, USA

Annual General Meeting

Feb 28, 2019
Basel, Switzerland

[Visit the Annual General Meeting section](#) ^[18]

Citi's 7th Annual IO Leadership Summit

Feb 19, 2019
New York, USA

Guggenheim Partners Oncology Day

Feb 14, 2019
New York, USA

Fourth Quarter and Full Year Results 2018 and Annual Report 2018 publication

Jan 30, 2019
Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) ^[157]

[Deutsch \(PDF 0.1 MB\)](#) ^[158]

[Français \(PDF 0.2 MB\)](#) ^[159]

[Condensed financial report \(PDF 0.6 MB\)](#) ^[160]

[Read the presentation transcript](#) ^[161]

[Download the podcast \(MP3 51 MB\)](#) [162]

[Download the presentation \(PDF 3.4 MB\)](#) [163]

[Download the Annual Report 2018 \(PDF 3.8 MB\)](#) [164]

J.P. Morgan Healthcare Conference

Jan 07, 2019
San Francisco, USA

[Download the presentation \(PDF 1.9 MB\)](#) [165]

2018 Archive [166]

Citi Healthcare Conference

Dec 05, 2018
New York, USA

Berenberg European Corporate Conference

Dec 05, 2018
London, UK

Alcon capital markets day in London

Dec 04, 2018
London, UK

[Download the agenda \(PDF 0.1 MB\)](#) [167]

[Download the presentation \(PDF 5.9 MB\)](#) [168]

Alcon capital markets day in New York

Nov 27, 2018
New York, USA

[Read the media release](#) [169]

[Download the agenda \(PDF 0.1 MB\)](#) ^[167]

[Download the presentation \(PDF 5.9 MB\)](#) ^[170]

Jefferies London Healthcare Conference

Nov 14, 2018

London, UK

UBS European Conference

Nov 13, 2018

London, UK

SG European ESG/SRI Conference Paris

Nov 13, 2018

Paris, France

Credit Suisse Healthcare Conference

Nov 12-13, 2018

Phoenix, USA

HSBC Healthcare Day

Nov 12, 2018

Frankfurt, Germany

Morningstar's Management Behind the Moat Conference

Nov 07-08, 2018

Chicago, USA

Restatement for the Innovative Medicines and Alcon Segments 2015 and 2016 following the OTC Transfer

Nov 07, 2018

[Download the presentation \(PDF 0.2 MB\)](#) ^[171]

Novartis R&D update

Nov 05, 2018
London, UK

[Read the media release](#) [172]

[Download the agenda \(PDF 0.1 MB\)](#) [173]

[Download the presentation \(PDF 5.6 MB\)](#) [174]

ESMO Investor Call

Oct 22, 2018

[Download the podcast \(MP3 5.1 MB\)](#) [175]

[Download the presentation \(PDF 0.9 MB\)](#) [176]

Third quarter results 2018

Oct 18, 2018
Basel, Switzerland

Media release

[English \(PDF 0.1 MB\)](#) [177]

[Deutsch \(PDF 0.1 MB\)](#) [178]

[Français \(PDF 0.2 MB\)](#) [179]

[Interim financial report \(PDF 0.7 MB\)](#) [180]

[Read the presentation transcript](#) [181]

[Download the podcast \(MP3 38 MB\)](#) [182]

[Download the presentation \(PDF 1.8 MB\)](#) [183]

Bernstein's Strategic Decisions Conference

Sep 26, 2018
London, UK

Novartis ESG conference call

Sep 17, 2018
Basel, Switzerland

[Download the presentation \(PDF 2.5 MB\)](#) [184]

[Download the podcast \(MP3 26 MB\)](#) [185]

Bank of America Merrill Lynch Global Healthcare Conference

Sep 13, 2018
London, UK

Morgan Stanley Conference

Sep 12-13, 2018
New York, USA

UBS Best of Switzerland Conference 2018

Sep 06-07, 2018
Zurich, Switzerland

Wells Fargo Healthcare Conference

Sep 05, 2018
Boston, USA

Second quarter results 2018

Jul 18, 2018
Basel, Switzerland

Media release

[English \(PDF 0.1 MB\)](#) [186]

[Deutsch \(PDF 0.1 MB\)](#) [187]

[Français \(PDF 0.2 MB\)](#) [188]

[Interim financial report \(PDF 0.5 MB\)](#) [189]

[Download the presentation \(PDF 1.8 MB\)](#) [190]

[Download the podcast \(MP3 93 MB\)](#) [191]

Novartis concludes strategic review of Alcon and initiates share buyback

Jun 29, 2018

[Download the presentation \(PDF 1.2 MB\)](#) [192]

[Download the podcast \(MP3 17 MB\)](#) [193]

Read the media release:

English ^[194]

Deutsch ^[195]

Français ^[196]

Source URL: <https://www.novartis.com/investors/event-calendar>

Links

- [1] <https://onlinexperiences.com/Launch/QReg/ShowUUID=B4208415-ECFC-4F0D-8E83-3921EA57A562&LangLocaleID=1033>
- [2] <https://www.novartis.com/investors/event-calendar#tab-2>
- [3] <https://onlinexperiences.com/Launch/QReg/ShowUUID=A07ADD67-5A5E-402A-83DF-9635E7DC9742&LangLocaleID=1033>
- [4] <https://www.novartis.com/sites/www.novartis.com/files/2021-06-novartis-asco-call-presentation.pdf>
- [5] <https://survey.alchemer.eu/s3/90325786/Registration-Materiality-Assessment-Webinar-1-June-2021>
- [6] <https://edge.media-server.com/mmc/p/ikivbyzp>
- [7] <https://www.novartis.com/sites/www.novartis.com/files/novartis-may-2021-cardiovascular-update.pdf>
- [8] <https://www.novartis.com/sites/www.novartis.com/files/novartis-cardiovascular-update.mp3>
- [9] <https://www.novartis.com/sites/www.novartis.com/files/q1-2021-media-release-en.pdf>
- [10] <https://www.novartis.com/sites/www.novartis.com/files/q1-2021-media-release-de.pdf>
- [11] <https://www.novartis.com/sites/www.novartis.com/files/q1-2021-media-release-fr.pdf>
- [12] <https://www.novartis.com/sites/www.novartis.com/files/2021-04-interim-financial-report-en.pdf>
- [13] <https://edge.media-server.com/mmc/p/8htwmdkn>
- [14] <https://www.novartis.com/investors/financial-data/quarterly-results/2021-q1-transcript>
- [15] <https://www.novartis.com/sites/www.novartis.com/files/q1-2021-investor-presentation.mp3>
- [16] <https://www.novartis.com/sites/www.novartis.com/files/q1-2021-investor-presentation.pdf>
- [17] <https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-apr-2021-update.pdf>
- [18] <https://www.novartis.com/investors/shareholder-information/annual-general-meeting>
- [19] <https://wsw.com/webcast/svbleerink47/nvs/2471936>
- [20] <https://edge.media-server.com/mmc/p/5tu3izry>
- [21] <https://www.novartis.com/sites/www.novartis.com/files/novartis-2021-entresto-label-update-presentation.mp3>
- [22] <https://www.novartis.com/sites/www.novartis.com/files/novartis-2021-entresto-label-update-presentation.pdf>
- [23] <http://www.kaltura.com/tiny/wjead>
- [24] <https://www.novartis.com/sites/www.novartis.com/files/novartis-materiality-assessment-2021-kickoff-webinar-presentation.pdf>
- [25] <https://www.novartis.com/sites/www.novartis.com/files/q4-2020-media-release-en.pdf>
- [26] <https://www.novartis.com/sites/www.novartis.com/files/q4-2020-media-release-de.pdf>
- [27] <https://www.novartis.com/sites/www.novartis.com/files/q4-2020-media-release-fr.pdf>
- [28] <https://www.novartis.com/sites/www.novartis.com/files/2021-01-interim-financial-report-en.pdf>
- [29] <https://edge.media-server.com/mmc/p/g655yyy5>
- [30] <https://www.novartis.com/investors/financial-data/quarterly-results/2020-q4-and-full-year-results-transcript>
- [31] <https://www.novartis.com/sites/www.novartis.com/files/q4-2020-investor-presentation.mp3>
- [32] <https://www.novartis.com/sites/www.novartis.com/files/q4-2020-investor-presentation.pdf>
- [33] <https://www.novartis.com/sites/www.novartis.com/files/q4-2020-investor-interactive-deck.pdf>
- [34] <https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-january-2021-update.pdf>
- [35] <https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2020.pdf>
- [36] <https://www.novartis.com/investors/novartis-annual-reporting-suite>
- [37] <https://jpmorgan.metameetings.net/events/healthcare21/sessions/35412->

novartis/webcast?gpu_only=true&kiosk=true

[38] <https://www.novartis.com/sites/www.novartis.com/files/2021-novartis-vas-narasimhan-jpmorgan-presentation.pdf>

[39] <https://www.novartis.com/investors/event-calendar#tab-3>

[40] <https://www.surveygizmo.eu/s3/90283352/Registration-CCI-Summit-Dec9>

[41] <https://www.novartis.com/sites/www.novartis.com/files/agenda-co-creating-impact-summit-dec-2020.pdf>

[42] <https://www.novartis.com/sites/www.novartis.com/files/2020-10-mnm-agenda.pdf>

[43] <https://www.novartis.com/investors/event-calendar/meet-novartis-management>

[44] <https://www.surveygizmo.eu/s3/90277055/Registration-MA-Webinar-Measuring-and-Evaluating-Social-Outcomes-of-Access-Initiatives>

[45] <https://www.novartis.com/sites/www.novartis.com/files/q3-2020-media-release-en.pdf>

[46] <https://www.novartis.com/sites/www.novartis.com/files/q3-2020-media-release-de.pdf>

[47] <https://www.novartis.com/sites/www.novartis.com/files/q3-2020-media-release-fr.pdf>

[48] <https://www.novartis.com/sites/www.novartis.com/files/2020-10-interim-financial-report-en.pdf>

[49] <https://edge.media-server.com/mmc/p/3soac2di>

[50] <https://www.novartis.com/investors/financial-data/quarterly-results/2020-q3-transcript>

[51] <https://www.novartis.com/sites/www.novartis.com/files/q3-2020-investor-presentation.mp3>

[52] <https://www.novartis.com/sites/www.novartis.com/files/q3-2020-investor-presentation.pdf>

[53] <https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-october-2020-update.pdf>

[54] <https://edge.media-server.com/mmc/p/dkpqeo33>

[55] <https://www.novartis.com/sites/www.novartis.com/files/2020-09-novartis-esg-day-presentation.pdf>

[56] <https://www.novartis.com/news/media-releases/novartis-announces-ambitious-esg-targets-increase-access-medicines-and-achieve-full-carbon-neutrality>

[57] <https://edge.media-server.com/mmc/p/pg6stjhg>

[58] <https://www.novartis.com/sites/www.novartis.com/files/2020-08-kesimpta-us-approval-investor-call-presentation.mp3>

[59] <https://www.novartis.com/sites/www.novartis.com/files/2020-08-kesimpta-us-approval-investor-call-presentation.pdf>

[60] <https://www.surveygizmo.eu/s3/90251566/Registration-MA-Webinar-Health-is-Wealth>

[61] <https://www.novartis.com/sites/www.novartis.com/files/q2-2020-media-release-en.pdf>

[62] <https://www.novartis.com/sites/www.novartis.com/files/q2-2020-media-release-de.pdf>

[63] <https://www.novartis.com/sites/www.novartis.com/files/q2-2020-media-release-fr.pdf>

[64] <https://www.novartis.com/sites/www.novartis.com/files/2020-07-interim-financial-report-en.pdf>

[65] <https://edge.media-server.com/mmc/p/gmoigdbg>

[66] <https://www.novartis.com/investors/financial-data/quarterly-results/2020-q2-transcript>

[67] <https://www.novartis.com/sites/www.novartis.com/files/q2-2020-investor-presentation.mp3>

[68] <https://www.novartis.com/sites/www.novartis.com/files/q2-2020-investor-presentation.pdf>

[69] <https://www.novartis.com/sites/www.novartis.com/files/environmental-social-and-governance-july-2020-update.pdf>

[70] <https://www.surveygizmo.eu/s3/90244617/Registration-MA-Webinar-Embracing-double-materiality>

[71] <https://edge.media-server.com/mmc/p/482pvrnh>

[72] <https://www.novartis.com/sites/www.novartis.com/files/2020-06-novartis-oncology-pipeline-update-presentation.mp3>

[73] <https://www.novartis.com/sites/www.novartis.com/files/2020-06-novartis-oncology-pipeline-update-presentation.pdf>

[74] <https://www.surveygizmo.eu/s3/90236163/Registration-MA-Webinar-Rethinking-Healthcare-System-Strengthening>

[75] <https://www.novartis.com/sites/www.novartis.com/files/q1-2020-media-release-en.pdf>

[76] <https://www.novartis.com/sites/www.novartis.com/files/q1-2020-media-release-de.pdf>

[77] <https://www.novartis.com/sites/www.novartis.com/files/q1-2020-media-release-fr.pdf>

[78] <https://www.novartis.com/sites/www.novartis.com/files/2020-04-interim-financial-report-en.pdf>

[79] <https://www.novartis.com/investors/financial-data/quarterly-results/2020-q1-transcript>

[80] <https://www.novartis.com/sites/www.novartis.com/files/q1-2020-investor-presentation.mp3>

[81] <https://www.novartis.com/sites/www.novartis.com/files/q1-2020-investor-presentation.pdf>

[82] <https://www.novartis.com/investors/environmental-social-and-governance/april-2020-update>

[83] <https://www.novartis.com/sites/www.novartis.com/files/2020-03-avexis-investor-call-presentation.mp3>

[84] <https://www.novartis.com/sites/www.novartis.com/files/2020-03-avexis-investor-call-presentation.pdf>

[85] <https://www.novartis.com/sites/www.novartis.com/files/q4-2019-media-release-en.pdf>

[86] <https://www.novartis.com/sites/www.novartis.com/files/q4-2019-media-release-de.pdf>

[87] <https://www.novartis.com/sites/www.novartis.com/files/q4-2019-media-release-fr.pdf>

[88] <https://www.novartis.com/sites/www.novartis.com/files/2020-01-interim-financial-report-en.pdf>

[89] <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q4-and-full-year-results-transcript>

[90] <https://www.novartis.com/sites/www.novartis.com/files/q4-2019-investor-presentation.mp3>

[91] <https://www.novartis.com/sites/www.novartis.com/files/q4-2019-investor-presentation.pdf>

[92] <https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2019.pdf>

[93] <https://www.novartis.com/investors/event-calendar/jp-morgan-healthcare-conference-2020-presentation-transcript>

[94] <https://www.novartis.com/sites/www.novartis.com/files/2020-novartis-vas-narasimhan-jpmorgan-presentation.mp3>

[95] <https://www.novartis.com/sites/www.novartis.com/files/2020-novartis-vas-narasimhan-jpmorgan-q-a.mp3>

[96] <https://www.novartis.com/sites/www.novartis.com/files/2020-novartis-vas-narasimhan-jpmorgan-presentation.pdf>

[97] <https://www.novartis.com/investors/event-calendar#tab-4>

[98] <https://www.novartis.com/news/media-releases/novartis-expects-sustain-long-term-growth-robust-pipeline-25-potential-blockbusters-highlighted-rd-day>

[99] <https://www.novartis.com/sites/www.novartis.com/files/2019-r-d-day-investor-agenda.pdf>

[100] <https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf>

[101] <https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global>

[102] <https://www.novartis.com/investors/event-calendar/novartis-enter-into-agreement-to-acquire-the-medicines-company>

[103] <https://www.novartis.com/sites/www.novartis.com/files/novartis-agreement-acquire-medicines-company-investor-presentation.mp3>

[104] <https://www.novartis.com/sites/www.novartis.com/files/novartis-agreement-acquire-medicines-company-investor-presentation.pdf>

[105] <https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-en.pdf>

[106] <https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-de.pdf>

[107] <https://www.novartis.com/sites/www.novartis.com/files/q3-2019-media-release-fr.pdf>

[108] <https://www.novartis.com/sites/www.novartis.com/files/2019-10-interim-financial-report-en.pdf>

[109] <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q3-transcript>

[110] <https://www.novartis.com/sites/www.novartis.com/files/q3-2019-ir-presentation.pdf>

[111] <https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-and-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept>

[112] <https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-beovu-fda-approval-investor-call-presentation.pdf>

[113] <https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-beovu-fda-approval-investor-call-presentation.mp3>

[114] <https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-esmo-investor-call-presentation.mp3>

[115] <https://www.novartis.com/sites/www.novartis.com/files/2019-10-novartis-esmo-investor-call-presentation.pdf>

[116] <https://www.novartis.com/sites/www.novartis.com/files/2019-09-novartis-ectrims-investor-call-presentation.mp3>

[117] <https://www.novartis.com/sites/www.novartis.com/files/2019-09-novartis-ectrims-investor-call-presentation.pdf>

[118] <https://www.novartis.com/sites/www.novartis.com/files/2019-09-esg-presentation.mp3>

[119] <https://www.novartis.com/sites/www.novartis.com/files/2019-09-esg-presentation.pdf>

[120] <https://www.novartis.com/sites/www.novartis.com/files/zolgensma-update-media-release-august-2019.pdf>

[121] <https://www.novartis.com/sites/www.novartis.com/files/zolgensma-update-recording.mp3>

[122] <https://www.novartis.com/sites/www.novartis.com/files/q2-2019-media-release-en.pdf>

[123] <https://www.novartis.com/sites/www.novartis.com/files/q2-2019-media-release-de.pdf>

[124] <https://www.novartis.com/sites/www.novartis.com/files/q2-2019-media-release-fr.pdf>

[125] <https://www.novartis.com/sites/www.novartis.com/files/2019-07-interim-financial-report-en.pdf>

[126] <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q2-transcript>

[127] <https://www.novartis.com/sites/www.novartis.com/files/q2-2019-ir-presentation.mp3>

[128] <https://www.novartis.com/sites/www.novartis.com/files/q2-2019-ir-presentation.pdf>

[129] <https://www.novartis.com/sites/www.novartis.com/files/2019-06-novartis-asco-investor-event-presentation.pdf>

[130] <https://www.novartis.com/news/media-releases/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma>

[131] <https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families>

[132] https://www.avexis.com/content/pdf/prescribing_information.pdf

[133] <https://www.novartis.com/news/media-releases/fda-approves-novartis-piqray-first-and-only-treatment-specifically-patients-pik3ca-mutation-hrher2-advanced-breast-cancer>

[134] <https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.pdf>

[135] <https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.mp3>

[136] <https://www.novartis.com/news/media-releases/novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-strategy-meet-novartis-management-investor-event>

[137] <https://www.novartis.com/sites/www.novartis.com/files/2019-05-meet-novartis-management-presentation.pdf>

[138] <https://www.novartis.com/sites/www.novartis.com/files/2019-05-meet-the-management-agenda.pdf>

[139] <https://www.novartis.com/news/media-releases/novartis-acquire-xiidra-expanding-front-eye-portfolio-and-strengthening-leadership-eye-care>

[140] <https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-xiidra-ir-call-presentation.mp3>

[141] <https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-xiidra-ir-call-presentation.pdf>

[142] <https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-avexis-aan-presentation.mp3>

[143] <https://www.novartis.com/sites/www.novartis.com/files/2019-05-novartis-avexis-aan-presentation.pdf>

[144] <https://www.novartis.com/sites/www.novartis.com/files/q1-2019-media-release-en.pdf>

[145] <https://www.novartis.com/sites/www.novartis.com/files/q1-2019-media-release-de.pdf>

[146] <https://www.novartis.com/sites/www.novartis.com/files/q1-2019-media-release-fr.pdf>

[147] <https://www.novartis.com/sites/www.novartis.com/files/2019-04-interim-financial-report-en.pdf>

[148] <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q1-transcript>

[149] <https://www.novartis.com/sites/www.novartis.com/files/q1-2019-ir-presentation.mp3>

[150] <https://www.novartis.com/sites/www.novartis.com/files/q1-2019-ir-presentation.pdf>

[151] <https://www.novartis.com/sites/www.novartis.com/files/novartis-2017-2018-results-continuing-operations.pdf>

[152] <https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease>

[153] <https://www.novartis.com/sites/www.novartis.com/files/novartis-mayzent-fda-approval-investor-presentation.pdf>

[154] <https://www.novartis.com/sites/www.novartis.com/files/novartis-mayzent-fda-approval-investor-presentation.mp3>

[155] <https://www.novartis.com/sites/www.novartis.com/files/alcon-20f-filing-2019.pdf>

[156] <https://www.sec.gov/Archives/edgar/data/1167379/000104746919001507/0001047469-19-001507-index.htm>

[157] <https://www.novartis.com/sites/www.novartis.com/files/q4-2018-media-release-en.pdf>

[158] <https://www.novartis.com/sites/www.novartis.com/files/q4-2018-media-release-de.pdf>

[159] <https://www.novartis.com/sites/www.novartis.com/files/q4-2018-media-release-fr.pdf>

[160] <https://www.novartis.com/sites/www.novartis.com/files/2019-01-financial-report-en.pdf>

[161] <https://www.novartis.com/investors/financial-data/quarterly-results/2018-q4-and-full-year-results-transcript>

[162] <https://www.novartis.com/sites/www.novartis.com/files/q4-2018-ir-presentation.mp3>

[163] <https://www.novartis.com/sites/www.novartis.com/files/q4-2018-ir-presentation.pdf>

[164] <https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2018-en.pdf>

[165] <https://www.novartis.com/sites/www.novartis.com/files/2019-novartis-jpmorgan-presentation.pdf>

[166] <https://www.novartis.com/investors/event-calendar#tab-5>

[167] <https://www.novartis.com/sites/www.novartis.com/files/2018-investors-alcon-cmd-agenda.pdf>

[168] <https://www.novartis.com/sites/www.novartis.com/files/2018-investors-alcon-cmd-presentation-dec4.pdf>

[169] <https://www.novartis.com/news/media-releases/alcon-highlight-its-vision-strategy-and-benefits-standalone-company-investors-and-analysts-new-york-and-london>

[170] <https://www.novartis.com/sites/www.novartis.com/files/2018-investors-alcon-cmd-presentation.pdf>

[171] <https://www.novartis.com/sites/www.novartis.com/files/novartis-financials-2015-2016-updated-segment-reporting.pdf>

[172] <https://www.novartis.com/news/media-releases/novartis-rd-update-highlights-industry-leading-development-pipeline-including-potential-blockbusters-and-advanced-therapy-platforms>

[173] <https://www.novartis.com/sites/www.novartis.com/files/2018-11-r-d-day-investor-agenda.pdf>

[174] <https://www.novartis.com/sites/www.novartis.com/files/2018-11-05-r-d-day-investor-presentation.pdf>

[175] <https://www.novartis.com/sites/www.novartis.com/files/2018-novartis-esmo-presentation.mp3>

[176] <https://www.novartis.com/sites/www.novartis.com/files/2018-novartis-esmo-presentation.pdf>

[177] <https://www.novartis.com/sites/www.novartis.com/files/q3-2018-media-release-en.pdf>

[178] <https://www.novartis.com/sites/www.novartis.com/files/q3-2018-media-release-de.pdf>

[179] <https://www.novartis.com/sites/www.novartis.com/files/q3-2018-media-release-fr.pdf>

[180] <https://www.novartis.com/sites/www.novartis.com/files/2018-10-interim-financial-report-en.pdf>

[181] <https://www.novartis.com/investors/financial-data/quarterly-results/2018-q3-transcript>

[182] <https://www.novartis.com/sites/www.novartis.com/files/q3-2018-ir-presentation.mp3>

[183] <https://www.novartis.com/sites/www.novartis.com/files/q3-2018-ir-presentation.pdf>

[184] <https://www.novartis.com/sites/www.novartis.com/files/2018-09-esg-presentation.pdf>

[185] <https://www.novartis.com/sites/www.novartis.com/files/2018-09-esg-presentation.mp3>

[186] <https://www.novartis.com/sites/www.novartis.com/files/q2-2018-media-release-en.pdf>

[187] <https://www.novartis.com/sites/www.novartis.com/files/q2-2018-media-release-de.pdf>

[188] <https://www.novartis.com/sites/www.novartis.com/files/q2-2018-media-release-fr.pdf>

[189] <https://www.novartis.com/sites/www.novartis.com/files/2018-07-interim-financial-report-en.pdf>

[190] <https://www.novartis.com/sites/www.novartis.com/files/q2-2018-ir-presentation.pdf>

[191] <https://www.novartis.com/sites/www.novartis.com/files/q2-2018-ir-presentation.mp3>

[192] <https://www.novartis.com/sites/www.novartis.com/files/2018-06-29-novartis-alcon-investor-presentation.pdf>

[193] <https://www.novartis.com/sites/www.novartis.com/files/2018-06-29-novartis-alcon-investor-presentation.mp3>

[194] <https://www.novartis.com/news/media-releases/novartis-announces-intention-look-for-shareholder-approval-100-spinoff-alcon-eye-care-devices-business-initiates-share-buyback-usd-5-bn>

[195] <https://www.novartis.com/news/media-releases/novartis-gibt-absicht-bekannt-die-genehmigung-der-aktionare-fur-einen-100igen-spin-des-geschäfts-mit-ophthalmologischen-produkten-von-alcon-einzuholen-und>

[196] <https://www.novartis.com/news/media-releases/novartis-annonce-son-intention-de-solliciter-lapprobation-des-actionnaires-pour-la-scission-100-dalcon-sa-division-de-produits-ophtalmologiques-et-initie-un>